Report Overview

The vernal keratoconjunctivitis market was valued at USD 436.90 Million in 2023, driven by advances in treatment options across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032, with the values likely to reach USD 744.42 Million by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

  • In February 2024, Harrow, Inc., a United States-based eye care pharmaceutical company, and Apotex Inc., a Canadian pharmaceutical corporation, formed an exclusive partnership to promote VERKAZIA®, a treatment for vernal keratoconjunctivitis, to enhance access and expand the market reach.
  • The ongoing research and development efforts to improve treatment options for vernal keratoconjunctivitis are expected to increase market growth.
  • The rise in new drug approvals by regulatory agencies like the United States FDA is a significant market trend.

Vernal Keratoconjunctivitis Market Overview

Vernal keratoconjunctivitis is a long-lasting allergic condition triggered by sensitivity to allergens found in the air. Younger males are the ones that are more commonly affected, showing symptoms like itching, sensitivity to light, redness, and discharge of mucus. The rise in vernal keratoconjunctivitis cases, especially in adults, is driving the market growth. Additionally, there is a growing preference for using immunomodulatory therapies, which are poised to impact the market dynamics in the forecast period.

Vernal Keratoconjunctivitis Market Growth Drivers

Increasing Recognition of Vernal Keratoconjunctivitis Cases in Adults to Drive Market Growth

The market for vernal keratoconjunctivitis is expanding as more adult cases are identified. A United States-based study demonstrated that approximately 10% of cases persist into adulthood or arise post-puberty, broadening the patient population and necessitating new treatments to address issues, thereby stimulating market expansion.

Vernal Keratoconjunctivitis Market Trends

Vernal Keratoconjunctivitis Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment

  • Nonsteroidal Anti-inflammatory Drugs - NSAIDs 
  • Mast Cell Stabilizers  
  • Antihistamines 
  • Topical Corticosteroids 
  • Cyclosporine 
  • Others

Market Breakup by Dosage Form

  • Ointment 
  • Gel 
  • Tablets 
  • Others

Market Breakup by Distribution Channel

  • Hospitals and Clinics 
  • Online Pharmacies 
  • Retail Pharmacies 
  • Others

Market Breakup by Region

  • United States 
  • EU-4 and the United Kingdom 
    • Germany 
    • France 
    • Italy 
    • Spain 
    • United Kingdom 
  • Japan 
  • India

Vernal Keratoconjunctivitis Market Share

Segmentation Based on Treatment to Witness Substantial Growth

Based on the treatment, the market is segmented into nonsteroidal anti-inflammatory drugs – NSAIDs, mast cell stabilizers, antihistamines, topical corticosteroids, cyclosporine, and others. Topical corticosteroids are expected to dominate the market share as they remain the most widely used option due to their effectiveness in rapidly reducing inflammation and alleviating symptoms like itching, pain, and sensitivity to light.

Vernal Keratoconjunctivitis Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is one of the leading markets owing to the high prevalence of conjunctivitis, coupled with an increased demand for effective treatments. With improved healthcare services and accessibility, the United States market for vernal keratoconjunctivitis is projected to witness significant growth in the coming years.

Leading Players in the Vernal Keratoconjunctivitis Market

The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical, is a Japanese company specialized specializing in ophthalmology, was granted FDA authorization in June 2021, for Verkazia, an eye drop medication containing cyclosporine, to manage vernal keratoconjunctivitis.

Novartis Pharmaceuticals Corporation

Novartis is a cutting-edge pharmaceutical company that introduced ALOMIDE eye drops for managing vernal kerato...

Senju Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd., headquartered in Japan, has a prominent presence in the market. The company sp...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include Akari Therapeutics Plc., Allakos Inc., Satellos Bioscience Inc., Viatris Inc., Aldeyra Therapeutics, Inc., Laboratoires Thea S.A.S., and Astellas Pharma Inc.

Key Questions Answered in the Vernal Keratoconjunctivitis Market

  • What was the vernal keratoconjunctivitis market value in 2023?
  • What is the vernal keratoconjunctivitis market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is the market segmentation based on the treatment?
  • What is the market breakup based on the dosage form?
  • What is the market breakup based on the distribution channel?
  • What are the major factors aiding the vernal keratoconjunctivitis market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Which regional market is expected to dominate the market share in the forecast period?
  • Which country is likely to experience elevated growth during the forecast period?
  • Who are the key players involved in the vernal keratoconjunctivitis market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment
  • Dosage Form
  • Distribution Channel
  • Region
Breakup by Treatment
  • Nonsteroidal Anti-inflammatory Drugs - NSAIDs
  • Mast Cell Stabilizers
  • Antihistamines
  • Topical Corticosteroids
  • Cyclosporine
  • Others
Breakup by Dosage Form
  • Ointment
  • Gel
  • Tablets
  • Others
Breakup by Distribution Channel
  • Hospitals and Clinics
  • Online Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Santen Pharmaceutical Co., Ltd.
  • Novartis Pharmaceuticals Corporation
  • Senju Pharmaceutical Co., Ltd.
  • Akari Therapeutics Plc.
  • Allakos Inc.
  • Satellos Bioscience Inc.
  • Viatris Inc.
  • Aldeyra Therapeutics, Inc.
  • Laboratoires Thea S.A.S.
  • Astellas Pharma Inc.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124